Blood test for 50+ cancers boosts early detection 6.5-fold in major trial

For generations, cancer has hidden in the body's silence until it speaks too loudly to answer. A landmark clinical trial now suggests that a single blood draw, read by machine-learning algorithms trained to recognize the molecular signatures of malignancy, may begin to change that equation — detecting more than fifty cancer types earlier, when the possibility of cure still exists. The PATHFINDER 2 study, enrolling nearly 36,000 adults across North America, found that adding the Galleri multi-cancer test to standard screening increased cancer detection 6.5-fold, with the majority of newly found